MedTrace Logo

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

NCT06323447 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2024-10-09

No results posted yet for this study

Summary

Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

PointCheck

Binary classification of severe neutropenia

Sponsors & Collaborators

  • Leuko Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Carlos Castro Gonzalez, PhD · Leuko Labs

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-03-30
Completion
2026-04-28
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323447 on ClinicalTrials.gov